Across TCGA pan-cancer cohorts, SLC29A3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC29A3 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SLC29A3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC29A3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM and LUSC are the cancer types where SLC29A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.991	0.673	.013	15	view →
LUSC	DFS	Median	All	0.136	0.791	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SLC29A3 tumor-vs-normal RNA expression · all SLC29A3 data types